For more than four decades, the Cancer Research and Treatment Fund (CR&T) has funded the world’s most promising physician-scientists, equipping them with resources to advance the treatment of various types of blood cancers including myeloproliferative neoplasms (MPNs), leukemia, non-Hodgkin’s lymphoma, Hodgkin’s disease and multiple myeloma as well as other common cancers such as breast and lung cancer.
About CR&T: Funding World-Class Cancer Research Organizations
Historically, CR&T has played a pivotal role in myeloproliferative neoplasm (MPN) cancer research. Since progressive blood cancers cannot be treated surgically, hematologists have been forced to focus on the development of biological and pharmacological treatments. At CR&T, we have been a major funder of research to improve treatments for leukemia and myeloproliferative neoplasms, based on our unwavering belief that blood cancer research holds the key to a cure for all types of malignancies.
Combined with recent advances in gene mapping, the work of CR&T associates has been instrumental in the development of new, molecule-targeting agents that address the genetic makeup of the cancer itself. This targeted form of therapy has produced a host of drugs that give new hope to today’s cancer patients.
Bringing Advances in Research to Cancer Patients
In the cancer research community, CR&T has developed a reputation as an extremely independent and agile funding organization. We intentionally avoid layers of bureaucracy so we can move swiftly and decisively, rapidly delivering funding for promising new cancer treatments.
As a bridge between the laboratory and patients, CR&T works tirelessly to earn the loyalty of friends and benefactors who share our commitment to advancing the fields of research and caregiving.